Why is CYDY information so confounding? The lin

Why is CYDY information so confounding?

The linked article has what seems like very important information: Seethamraju/Montefiore will run 60 patients out of 100 total in the longhaul trial, and this trial will begin in three weeks.

Why is this information published here?

Didn't yesterday's conference call say that the FDA had not yet approved the CYDY IND for longhaulers?

And what about the several other easter eggs in this article.

Why is this article publishing that the longhauler trial costs $5 million?

Why is this article publishing that the CD12 trial costs $10 million?

Who did they get this info from?

Probably the article statement that the FDA will evaluate the CD12 results "as early as next week" can be attributed to the article author's conflating 75% enrollment with the end of the CD12 trial, but no way they even get 75% enrollment complete next week.

If anyone can decode any of this, I would sure appreciate it.

I can offer one explanation, even though it might be totally preposterous.

Seethamraju is really pissed off, about what I couldn't say.

Several weeks ago Seethamraju stated unequivocally that the FDA has the CD12 interim results in their possession.

Subsequent to Seethamraju's claim on FDA CD12 FDA participation, Pourhassan completely and totally contradicted Seethamraju.

Maybe Seethamraju is pissed and has started a bit of his own publicity machine, complete with much more longhauler and CD12 information than CYDY or the FDA seem willing to provide.

Or not.